Whitehawk Therapeutics
WHWK
52 hedge funds and large institutions have $24.7M invested in Whitehawk Therapeutics in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 23 reducing their positions, and 22 closing their positions.
2,350% more call options, than puts
Call options by funds: $49K | Put options by funds: $2K
47% more capital invested
Capital invested by funds: $16.7M → $24.7M (+$7.92M)
1.91% more ownership
Funds ownership: 46.73% → 48.64% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
20% less funds holding
Funds holding: 65 → 52 (-13)
59% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 22
70% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$3.23M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.98M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$151K |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
+$139K |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$76K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Alerce Investment Management
Chicago,
Illinois
|
-$2.64M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$785K |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$744K |
| 4 |
Goldman Sachs
New York
|
-$225K |
| 5 |
Jane Street
New York
|
-$175K |
WHWK Hedge Fund Activity: Q3 2024 in Review
52 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q3 2024, worth a combined $24.7M — up 47% from $16.7M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of WHWK and 9 opened new positions — a net loss of 13 holders — while 23 trimmed existing stakes and 7 added.
The largest buyer was BML Capital Management, opening a new position worth an estimated $3.23M. The largest seller was Alerce Investment Management, cutting an estimated $2.64M.
- 52 institutional investors held Whitehawk Therapeutics (WHWK) as of Q3 2024, down from 65 in Q2 2024.
- Funds reported $24.7M of Whitehawk Therapeutics stock for Q3 2024, up 47% quarter-over-quarter.
- 9 funds opened new Whitehawk Therapeutics positions in Q3 2024 and 22 closed out, a net change of -13 holders.
- The largest Whitehawk Therapeutics buyer in Q3 2024 was BML Capital Management, an estimated $3.23M added.
- The largest Whitehawk Therapeutics seller in Q3 2024 was Alerce Investment Management, an estimated $2.64M sold.
Based on aggregated 13F filings for Q3 2024.